Immunocore announces clinical trial collaboration with Sanofi to evaluate Sanofi’s product candidate SAR444245, non-alpha IL-2, in combination with KIMMTRAK® in patients with metastatic cutaneous melanoma
…regulatory T cells KIMMTRAK, gp100 x CD3 ImmTAC bispecific protein, approved in metastatic uveal melanoma and demonstratedpromising survival data in metastatic cutaneous melanoma (OXFORDSHIRE, England & CONSHOHOCKEN,…














